Resources
About Us
Home Report
Store
Alzheimer’s Drugs Market
Alzheimer’s Drugs Market Size, Share, Forecast, & Trends Analysis by Drug (Cholinesterase Inhibitor [Donepezil, Galantamine, Rivastigmine], NMDA Receptor, Glutamate Regulator) Application (Disease Progression, Symptom Management) - Global Forecast to 2031
Report ID:MRHC - 1041264 Pages: 200 Sep-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursAlzheimer’s Drugs Market Size & Forecast
The Alzheimer’s Drugs Market is projected to reach $9.62 billion by 2031 at a CAGR of 9.8% from 2024 to 2031. The growth of this market can be attributed to various factors, such as the increasing burden of Alzheimer's disease globally, rising prevalence of risk factors, increase in research funding, introduction of innovative technologies, increasing number of approvals, and increasing number of clinical trials and pipeline products. Furthermore, growing research activities in developing countries, increase in awareness programs, initiatives by public and private organizations, use of combination drug therapy, and use of biomarkers and imaging techniques for diagnosis and management are expected to offer growth opportunities.
Alzheimer’s Drugs Market Growth Drivers
Increasing Burden of Alzheimer’s Disease Globally
Alzheimer’s is a brain condition that causes a progressive decline in memory, organizing, learning, and thinking skills. It is the most common type of dementia. Neurodegenerative disorders are considered a major burden on the healthcare system and one of the major causes of disabilities across the globe. The prevalence of neurogenerative disorders is increasing owing to factors such as aging, traumatic brain injury, genetic factors, stress, and other lifestyle risk factors. According to Alzheimer's Association (U.S.), a non-profit organization focused on Alzheimer’s disease care, research, and support, in 2024, the prevalence of Alzheimer’s disease increased to 6.9 million in age 65 and older population from 6.2 million in 2021. Thus, the rising prevalence of Alzheimer’s disease is expected to increase the demand for Alzheimer’s drugs.
Increase in Research Funding
The increasing prevalence of Alzheimer’s disease leads to the rising need for novel therapies for its treatment. Many public and private players provide funding for Alzheimer’s disease research to understand the disease pathology and develop the drug accordingly. According to the Alzheimer’s Association (U.S.), Alzheimer's and dementia research funding at the National Institutes of Health (NIH) reached USD 3.8 billion in 2023 from USD 2.8 billion in 2021. Some of the recent funding are as follows:
- In May 2024, NeuroTherapia (U.S.), a clinical trial pharmaceutical company, received a grant from the Alzheimer's Association as part of the cloud program to develop its NTRX-07 drug for the treatment of Alzheimer's disease (AD).
- In October 2023, the National Institute on Aging, part of the National Institutes of Health, provided funding of USD 151 million to the University of California San Francisco for the clinical trial of Alzheimer’s disease. The UCSF-led trial will combine an anti-amyloid with tau therapies to arrest disease progression.
Click here to: Get Free Sample Pages of this Report
Alzheimer’s Drugs Market Trends
Stem Cell Therapy in Alzheimer’s Treatment
Regenerative medicine is proving to be an effective therapy for various medical conditions, including cardiovascular diseases, ophthalmic diseases, oncology, neurological diseases, immunology & inflammation, musculoskeletal diseases, dermatological diseases, and others. Stem cell therapy has emerged as a promising treatment for Alzheimer's disease. Stem cells are self-replicating and undifferentiated and can divide & develop, proving beneficial properties for Alzheimer’s drug development. Stem cell therapy has the potential to reduce the deposition of amyloid β-protein (Aβ), thereby alleviating symptoms of memory loss. In 2018, the first stem cell therapy was approved in Japan for the treatment of Alzheimer’s disease developed by South Korea-based companies Nature Cell and the Biostar Stem Cell Research Institute. Since then, the research on stem cell therapy for the treatment of Alzheimer’s disease has increased. Many of the stem cell therapies are in clinical trials for Alzheimer’s disease.
Telehealth in Alzheimer's Disease
The traditional model of care for patients with Alzheimer’s disease involves long-term residential care, which can be more costly and not comfortable with many patients. Telehealth in Alzheimer’s disease involves the utilization of video conferencing to allow patients in remote locations to obtain treatment services. It provides patients and providers with a wide range of services, including consultations, clinical & educational programs, diagnosis and assessment, medication therapy management, and routine follow-up appointments. Patients who require convenient, affordable, and easily accessible mental health care can benefit from video-based telepsychiatry. Telehealth can manage symptoms of dementia at home before they turn into life-threatening issues. Many healthcare professionals use telehealth through video calls or mobile applications to remind patients about taking medications. Thus, increasing patient adherence to Alzheimer's disease drives the market growth of Alzheimer's drugs.
Alzheimer’s Drugs Market Opportunity
Combination Therapy for Alzheimer's Disease
Combination therapy includes the combination of two approved and used therapeutic agents in a fixed combination dosage for the treatment of Alzheimer's disease. Recent advancements in understanding the genetics of Alzheimer’s disease revealed the number of pathways involved in increasing the risk of Alzheimer’s disease. Targeting these pathways together in combination has the potential to provide an advantage for Alzheimer’s disease patients. At present, combined therapy with memantine plus one cholinesterase inhibitor (ChEI) is considered an effective treatment for low to moderate Alzheimer’s disease. In many randomized-controlled clinical trials (RCTs), this combination has demonstrated higher clinical efficacy than monotherapy.
Alzheimer’s Drugs Market Analysis: Key Findings
By Drug Type: In 2024, the Cholinesterase Inhibitors Segment to Dominate the Alzheimer’s Drugs Market
Based on drug type, the Alzheimer’s drugs market is segmented into cholinesterase inhibitors, NMDA receptor antagonists, glutamate regulators, and combination drugs. In 2024, the cholinesterase inhibitors segment is expected to account for the largest share of 46.9% of the Alzheimer’s drugs market. The drug works by decreasing the breakdown of acetylcholine, thus helping in the improvement of cognitive functions. The rising prevalence of Alzheimer’s disease and the increasing aging population are contributing to the demand for Cholinesterase inhibitors. The large share of the segment can be attributed to the high usage of these drugs for Alzheimer's treatment and the high number of drugs approved under this segment. At present, galantamine, donepezil, rivastigmine, and others are currently approved for the treatment of mild-to-moderate Alzheimer's disease (AD). Several studies have proven their efficacy for the treatment of the disease. According to an article published in the National Library of Medicine in 2022, cholinesterase inhibitors can slightly delay the loss of brain function in people who have mild to moderate Alzheimer’s disease.
By Application: In 2024, the Symptoms Management Segment to Dominate the Alzheimer’s Drugs Market
Based on application, the Alzheimer’s drugs market is segmented into disease progression and symptom management. In 2024, the symptoms management segment is expected to account for the largest share of 87.2% of the Alzheimer’s drugs market. Symptom management is considered an important step in Alzheimer’s disease treatment. The majority of the drugs used in the treatment of Alzheimer’s disease are for symptom management, thus contributing to the largest share of the segment. The symptom management drugs slow down the process of disease progression, thus helping in reducing the healthcare cost associated with it, thus increasing demand. Alzheimer's disease symptoms such as impaired judgment, memory loss, language loss, and other brain changes can make it harder to manage other health conditions, which can create further complications. Hence, the demand for symptom management is expected to increase.
Geographical Analysis
North America to Dominate the Market
In 2024, North America is expected to account for the largest share of the 43.0% of Alzheimer’s drugs market. The large share of the region is attributed to the increasing prevalence of Alzheimer’s disease, increasing funding for the development of Alzheimer’s treatment, the presence of key players, the rising number of clinical trials for Alzheimer’s drugs, and favorable reimbursement policies. For instance, in February 2024, the Centers for Medicare & Medicaid Services (U.S.), a federal agency within the United States Department of Health and Human Services that administers the Medicare program, covered a recently approved medication Leqembi (Lecanemab) used in the treatment of Alzheimer’s diseases. The drug is developed in partnership with Eisai Co., Ltd. (Japan) and Biogen Inc. (U.S.).
Moreover, the market in Asia-Pacific is slated to register the highest growth rate of 11.4% during the forecast period. The countries in the region, including China, India, and South Korea, are expected to offer significant opportunities for market growth. The growth in the country market is attributed to the growing pharmaceutical industry, supporting government initiatives, and a large number of clinical trials conducted in the region for Alzheimer’s. Also, government bodies in the region are providing funds for research on Alzheimer’s disease, which is driving the market’s growth. For instance, in August 2023, Bredis Healthcare (South Korea) received funding of USD 1.27 million for the development of diagnostic tests for Alzheimer's disease. The funding is provided by the South Korean Ministry of SMEs and Startups as a part of the Deep Tech Incubator Program for Startups (TIPS). Similarly, in May 2022, the Indian Health Service provided funding of USD 5 million to support urban Indian organizations, tribes, and tribal organizations to develop sustainable and comprehensive approaches to addressing Alzheimer’s disease.
Alzheimer’s Drugs Market: Key Companies
The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years (2020–2024). The key players operating in the Alzheimer’s drugs market are Biogen (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eisai Co., Ltd. (Japan), SUPERNUS PHARMACEUTICALS, INC. (U.S.), H. Lundbeck A/S (Denmark), AC Immune SA (Switzerland), Zydus Lifesciences Limited (India), Johnson & Johnson (U.S.), and Daiichi Sankyo Company (Japan).
Alzheimer’s Drugs Market Overview: Latest Developments from Key Industry Players
-
In July 2023, the U.S. FDA approved lecanemab through the Accelerated Approval Pathway for the treatment of Alzheimer’s disease. Lecanemab removes a sticky protein from the brain that is believed to cause Alzheimer’s disease progression. Eisai Co., Ltd. (Japan) and Biogen Inc. (U.S.) developed the drug in partnership.
- In December 2022, Eisai Co., Ltd. (Japan) collaborated with Washington University School of Medicine (U.S.) for the development of novel treatments for neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
- In March 2022, Corium, Inc. (U.S.) received U.S. FDA approval for ADLARITY (donepezil transdermal system) for the treatment of patients with Alzheimer’s disease. ADLARITY is a once-weekly patch to continuously deliver consistent doses of donepezil through the skin.
Alzheimer’s Drugs Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
200 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
9.8% |
|
Estimated Market Size (Value) |
$9.62 billion by 2031 |
|
Segments Covered |
By Drug Type
By Application
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Belgium, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), and Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa). |
|
Key Companies |
The key players operating in the Alzheimer’s drugs market are Biogen (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eisai Co., Ltd. (Japan), SUPERNUS PHARMACEUTICALS, INC. (U.S.), H. Lundbeck A/S (Denmark), AC Immune SA (Switzerland), Zydus Lifesciences Limited (India), Johnson & Johnson (U.S.), and Daiichi Sankyo Company (Japan). |
Key questions answered in the alzheimer’s drugs market report:
The Alzheimer’s drugs market report covers the qualitative and quantitative analysis of the market. It involves analyzing various market segments of Alzheimer’s drugs, such as type, source, production process, and end user, at the regional and country levels. The report also provides insights on factors impacting market growth, regulatory analysis, pipeline analysis, and Porter’s five forces analysis.
The Alzheimer’s drugs market is projected to reach $9.62 billion by 2031 at a CAGR of 9.8% from 2024 to 2031.
Among all the drug types studied in this report, in 2024, the cholinesterase inhibitors segment is expected to account for the largest share of 46.9% of the Alzheimer’s drugs market. The largest share of the segment is attributed to the increasing aging population, rising risk factors for Alzheimer's disease, increasing effectiveness of cholinesterase inhibitors, rising availability of cholinesterase inhibitors drugs, and rising accessibility and availability of cholinesterase inhibitors.
The growth of this market can be attributed to various factors, such as the increasing burden of Alzheimer's disease globally, rising prevalence of risk factors, increase in research funding, introduction of innovative technologies, increasing number of approvals, and increasing number of clinical trials and pipeline products. Furthermore, growing research activities in developing countries, increase in awareness programs, initiatives by public and private organizations, use of combination drug therapy, and use of biomarkers and imaging techniques for diagnosis and management are expected to offer growth opportunities.
The key players operating in the Alzheimer’s drugs market are Biogen (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eisai Co., Ltd. (Japan), SUPERNUS PHARMACEUTICALS, INC. (U.S.), H. Lundbeck A/S (Denmark), AC Immune SA (Switzerland), Zydus Lifesciences Limited (India), Johnson & Johnson (U.S.), and Daiichi Sankyo Company (Japan).
Among all the geographies studied in this report, Asia-Pacific is slated to register the highest growth rate of 11.4% during the forecast period. The growth in the region is attributed to the increasing incidence of Alzheimer’s disease, growing research activities, increased awareness, a large population, rising healthcare expenditures, technological advancements, and government support for clinical trials.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Increasing Burden of Alzheimer's Disease Globally
4.2.2. Rising Prevalence of Risk Factors
4.2.3. Increase in Research Funding
4.2.4. Introduction of Innovative Technologies
4.2.5. Increasing Number of Approvals
4.2.6. Increasing Number of Clinical Trials and Pipeline Products
4.3. Restraints
4.3.1. Possible Side Effects of Drugs
4.3.2. Use of Substitute Treatment
4.4. Opportunities
4.4.1. Growing Research Activities in Developing Countries
4.4.2 Increase in Awareness Programs
4.4.3. Initiatives by Public and Private Organizations
4.4.4. Use of Combination Drug Therapy
4.4.5. Use of Biomarkers and Imaging Techniques for Diagnosis and Management
4.5. Challenges
4.5.1. High Cost of Research and Development for Alzheimer’s Drugs
4.5.2. High Failure Rate in Clinical Trials for Alzheimer’s Drugs
4.5.3. Lengthy and Complex Regulatory Approval Process for Alzheimer’s Drugs
4.6. Factor Analysis
4.7. Trends
4.8. Regulatory Analysis
4.9. Pricing Analysis
4.10. Pipeline Analysis
4.11. Porter’s Five Force Analysis
5. Alzheimer’s Drugs Market Assessment—by Drug Type
5.1. Overview
5.2. Cholinesterase Inhibitors
5.2.1. Donepezil
5.2.2. Galantamine
5.2.3. Rivastigmine
5.3. NMDA receptor antagonists
5.4. Glutamate regulators
5.5. Combination Drugs
6. Alzheimer’s Drugs Market Assessment—by Application
6.1. Overview
6.2. Disease Progression
6.3. Symptoms Management
6.3.1. Dementia
6.3.2. Insomnia
6.3.3. Other Symptoms
7. Alzheimer’s Drugs Market Assessment—by Geography
7.1. Overview
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Switzerland
7.3.7. Belgium
7.3.8. Rest of Europe (RoE)
7.4. Asia-Pacific
7.4.1. Japan
7.4.2. China
7.4.3. India
7.4.4. South Korea
7.4.5. Rest of Asia-Pacific (RoAPAC)
7.5. Latin America
7.5.1. Brazil
7.5.2. Mexico
7.5.3. Argentina
7.5.4. Rest of Latin America (RoLATAM)
7.6. Middle East & Africa
7.6.1. UAE
7.6.2. Saudi Arabia
7.6.3. South Africa
7.6.4. Rest of Middle East & Africa
8. Competition Analysis
8.1. Overview
8.2. Key Growth Strategies
8.3. Competitive Benchmarking
8.4. Competitive Dashboard
8.4.1. Industry Leaders
8.4.2. Market Differentiators
8.4.3. Vanguards
8.4.4. Emerging Companies
8.5. Market Share Analysis/Market Ranking, by Key Players (2023)
9. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
9.1. Biogen
9.2. Novartis AG
9.3. F. Hoffmann-La Roche AG
9.4. AbbVie Inc.
9.5. Teva Pharmaceutical Industries Ltd.
9.6. Eisai Co., Ltd.
9.7. SUPERNUS PHARMACEUTICALS, INC.
9.8. H. Lundbeck A/S
9.9. AC Immune SA
9.10. Zydus Lifesciences Limited
9.11. Johnson & Johnson
9.12. Daiichi Sankyo Company
(Note: SWOT analyses of the top 5 companies will be provided.)
10. Appendix
10.1. Available Customization
10.2. Related Reports
List of Tables
Table 1 Global Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 2 Global Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 3 Global Cholinesterase Inhibitors Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Global Donepezil Market, by Country/Region, 2022–2031 (USD Million)
Table 5 Global Galantamine Market, by Country/Region, 2022–2031 (USD Million)
Table 6 Global Rivastigmine Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Global NMDA receptor antagonists Market, by Country/Region, 2022–2031 (USD Million)
Table 8 Global Glutamate Regulators Market, by Country/Region, 2022–2031 (USD Million)
Table 9 Global Combination Drugs Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 11 Global Alzheimer’s Drugs Market for Disease Progression, by Country/Region, 2022–2031 (USD Million)
Table 12 Global Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 13 Global Alzheimer’s Drugs Market for Symptoms Management, by Country/Region, 2022–2031 (USD Million)
Table 14 Global Alzheimer’s Drugs Market for Dementia, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Alzheimer’s Drugs Market for Insomnia, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Alzheimer’s Drugs Market for Other Symptoms, by Country/Region, 2022–2031 (USD Million)
Table 17 Global Alzheimer’s Drugs Market, by Country/Region, 2022–2031 (USD Million)
Table 18 North America: Alzheimer’s Drugs Market, by Country, 2022–2031 (USD Million)
Table 19 North America: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 20 North America: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 21 North America: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 22 North America: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 23 U.S.: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 24 U.S.: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 25 U.S.: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 26 U.S.: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 27 Canada: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 28 Canada: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 29 Canada: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 30 Canada: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 31 Europe: Alzheimer’s Drugs Market, by Country/Region, 2022–2031 (USD Million)
Table 32 Europe: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 33 Europe: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 34 Europe: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 35 Europe: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 36 Germany: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 37 Germany: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 38 Germany: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 39 Germany: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 40 France: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 41 France: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 42 France: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 43 France: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 44 U.K.: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 45 U.K.: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 46 U.K.: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 47 U.K.: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 48 Italy: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 49 Italy: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 50 Italy: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 51 Italy: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 52 Spain: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 53 Spain: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 54 Spain: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 55 Spain: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 56 Switzerland: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 57 Switzerland: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 58 Switzerland: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 59 Switzerland: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 60 Belgium: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 61 Belgium: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 62 Belgium: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 63 Belgium: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 64 Rest of Europe: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 65 Rest of Europe: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 66 Rest of Europe: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 67 Rest of Europe: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 68 Asia-Pacific: Alzheimer’s Drugs Market, by Country/Region, 2022–2031 (USD Million)
Table 69 Asia-Pacific: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 70 Asia-Pacific: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 71 Asia-Pacific: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 72 Asia-Pacific: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 73 China: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 74 China: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 75 China: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 76 China: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 77 Japan: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 78 Japan: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 79 Japan: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 80 Japan: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 81 India: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 82 India: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 83 India: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 84 India: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 85 South Korea: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 86 South Korea: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 87 South Korea: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 88 South Korea: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 89 Rest of Asia-Pacific: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 90 Rest of Asia-Pacific: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 91 Rest of Asia-Pacific: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 92 Rest of Asia-Pacific: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 93 Latin America: Alzheimer’s Drugs Market, by Country/Region, 2022–2031 (USD Million)
Table 94 Latin America: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 95 Latin America: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 96 Latin America: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 97 Latin America: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 98 Brazil: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 99 Brazil: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 100 Brazil: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 101 Brazil: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 102 Mexico: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 103 Mexico: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 104 Mexico: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 105 Mexico: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 106 Argentina: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 107 Argentina: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 108 Argentina: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 109 Argentina: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 110 Rest of Latin America: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 111 Rest of Latin America: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 112 Rest of Latin America: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 113 Rest of Latin America: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 114 Middle East & Africa: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 115 Middle East & Africa: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 116 Middle East & Africa: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 117 Middle East & Africa: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 118 UAE: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 119 UAE: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 120 UAE: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 121 UAE: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 122 Saudi Arabia: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 123 Saudi Arabia: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 124 Saudi Arabia: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 125 Saudi Arabia: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 126 South Africa: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 127 South Africa: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 128 South Africa: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 129 South Africa: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 130 Rest of Middle East & Africa: Alzheimer’s Drugs Market, by Drug Type, 2022–2031 (USD Million)
Table 131 Rest of Middle East & Africa: Cholinesterase Inhibitors Market, by Type, 2022–2031 (USD Million)
Table 132 Rest of Middle East & Africa: Alzheimer’s Drugs Market, by Application, 2022–2031 (USD Million)
Table 133 Rest of Middle East & Africa: Alzheimer’s Drugs Market for Symptoms Management, by Type, 2022–2031 (USD Million)
Table 134 Recent Developments, by Company, 2020–2024
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Global Alzheimer’s Drugs Market, by Drug Type, 2024 VS. 2031 (USD Million)
Figure 8 Global Alzheimer’s Drugs Market, by Application, 2024 VS. 2031 (USD Million)
Figure 9 Global Alzheimer’s Drugs Market, by Geography
Figure 10 Global Alzheimer’s Drugs Market, by Drug Type, 2024 VS. 2031 (USD Million)
Figure 11 Global Alzheimer’s Drugs Market, by Application, 2024 VS. 2031 (USD Million)
Figure 12 Global Alzheimer’s Drugs Market, by Geography, 2024 VS. 2031 (USD Million)
Figure 13 North America: Alzheimer’s Drugs Market Snapshot
Figure 14 Europe: Alzheimer’s Drugs Market Snapshot
Figure 15 Asia-Pacific: Alzheimer’s Drugs Market Snapshot
Figure 16 Latin America: Alzheimer’s Drugs Market Snapshot
Figure 17 Middle East & Africa: Alzheimer’s Drugs Market Snapshot
Figure 18 Key Growth Strategies Adopted by Leading Players, 2020–2024
Figure 19 Global Alzheimer’s Drugs Market: Competitive Benchmarking, by Drug Type
Figure 20 Global Alzheimer’s Drugs Market: Competitive Benchmarking, by Geography
Figure 21 Global Alzheimer’s Drugs Market: Competitive Dashboard
Figure 22 Global Alzheimer’s Drugs Market: Market Share Analysis/Market Ranking, By Key Players (2023)
Figure 23 Biogen: Financial Snapshot (2023)
Figure 24 Novartis AG: Financial Snapshot (2023)
Figure 25 F. Hoffmann-La Roche AG: Financial Snapshot (2023)
Figure 26 AbbVie Inc.: Financial Snapshot (2023)
Figure 27 Teva Pharmaceutical Industries Ltd.: Financial Snapshot (2023)
Figure 28 Eisai Co., Ltd.: Financial Snapshot (2023)
Figure 29 SUPERNUS PHARMACEUTICALS, INC.: Financial Snapshot (2023)
Figure 30 H. Lundbeck A/S: Financial Snapshot (2023)
Figure 31 AC Immune SA: Financial Snapshot (2023)
Figure 32 Zydus Lifesciences Limited: Financial Snapshot (2023)
Figure 33 Johnson & Johnson: Financial Snapshot (2023)
Figure 34 Daiichi Sankyo Company: Financial Snapshot (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Drug Delivery Devices Market - Global Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Aug-2024
General Anesthesia Drugs Market - Global Opportunity Analysis And Industry Forecast (2013-2018)
Published Date: Nov-2013
Patient Registry Software Market - Global Opportunity Analysis and Industry Forecast (2018-2023)
Published Date: Jul-2018
